Solara Active Pharma Sciences Ltd
NSE:SOLARA

Watchlist Manager
Solara Active Pharma Sciences Ltd Logo
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Watchlist
Price: 660.25 INR 0.14% Market Closed
Market Cap: 31.7B INR
Have any thoughts about
Solara Active Pharma Sciences Ltd?
Write Note

Solara Active Pharma Sciences Ltd
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Solara Active Pharma Sciences Ltd
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Income from Continuing Operations
-â‚ą5.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Income from Continuing Operations
â‚ą54.3B
CAGR 3-Years
40%
CAGR 5-Years
20%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Income from Continuing Operations
â‚ą44.9B
CAGR 3-Years
20%
CAGR 5-Years
22%
CAGR 10-Years
14%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Income from Continuing Operations
â‚ą111.4B
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
5%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Income from Continuing Operations
â‚ą18B
CAGR 3-Years
12%
CAGR 5-Years
27%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Income from Continuing Operations
â‚ą19.4B
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Solara Active Pharma Sciences Ltd
Glance View

Market Cap
31.7B INR
Industry
Pharmaceuticals

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.

SOLARA Intrinsic Value
588.77 INR
Overvaluation 11%
Intrinsic Value
Price

See Also

What is Solara Active Pharma Sciences Ltd's Income from Continuing Operations?
Income from Continuing Operations
-5.4B INR

Based on the financial report for Sep 30, 2024, Solara Active Pharma Sciences Ltd's Income from Continuing Operations amounts to -5.4B INR.

What is Solara Active Pharma Sciences Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 1Y
-1 576%

Over the last year, the Income from Continuing Operations growth was -1 576%.

Back to Top